{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:27:11Z","timestamp":1780363631315,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clcc.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T19:10:23Z","timestamp":1555009823000},"page":"159-166.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-4038","authenticated-orcid":false,"given":"Florian","family":"Huemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Schlintl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4055-3841","authenticated-orcid":false,"given":"Hubert","family":"Hackl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Rinnerthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-5613","authenticated-orcid":false,"given":"Lukas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2019.04.003_bib1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2019.04.003_bib2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2019.04.003_bib3","first-page":"283","article-title":"Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors","volume":"4","author":"Kanas","year":"2012","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.clcc.2019.04.003_bib4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2019.04.003_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.04.003_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","article-title":"NCCN guidelines insights: colon cancer, version 2.2018","volume":"16","author":"Benson","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clcc.2019.04.003_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clnu.2012.05.009","article-title":"Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results","volume":"32","author":"Thoresen","year":"2013","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clcc.2019.04.003_bib9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","article-title":"Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer","volume":"34","author":"Blauwhoff-Buskermolen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","article-title":"Diagnostic criteria for the classification of cancer-associated weight loss","volume":"33","author":"Martin","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib12","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1002\/cncr.21013","article-title":"Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care\u2014correlations with food intake, metabolism, exercise capacity, and hormones","volume":"103","author":"Fouladiun","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2019.04.003_bib13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A\u00a0practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"key":"10.1016\/j.clcc.2019.04.003_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-014-0130-5","article-title":"Assessing skeletal muscle mass: historical overview and state of the art","volume":"5","author":"Heymsfield","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clcc.2019.04.003_bib16","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","article-title":"Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image","volume":"97","author":"Shen","year":"2004","journal-title":"J\u00a0Appl Physiol (1985)"},{"key":"10.1016\/j.clcc.2019.04.003_bib17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0148607115604149","article-title":"Measuring abdominal circumference and skeletal muscle from a single cross-sectional computed tomography image: a step-by-step guide for clinicians using National Institutes of Health ImageJ","volume":"40","author":"Gomez-Perez","year":"2016","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.clcc.2019.04.003_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jcsm.12180","article-title":"Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer","volume":"8","author":"Rutten","year":"2017","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"issue":"4 suppl","key":"10.1016\/j.clcc.2019.04.003_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2018.36.4_suppl.611","article-title":"Regorafenib dose optimization study (ReDOS): randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC). ACCRU Network study","volume":"36","author":"Bekaii-Saab","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","article-title":"National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants","volume":"377","author":"Finucane","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2019.04.003_bib22","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib23","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-09-1525","article-title":"Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer","volume":"15","author":"Tan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.04.003_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/bjs.10063","article-title":"Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery","volume":"103","author":"Pecorelli","year":"2016","journal-title":"Br J Surg"},{"key":"10.1016\/j.clcc.2019.04.003_bib25","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1046\/j.1532-5415.2003.51362.x","article-title":"Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study","volume":"51","author":"Rolland","year":"2003","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.clcc.2019.04.003_bib26","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/sj.bjc.6602780","article-title":"Expression of the ubiquitin\u2013proteasome pathway and muscle loss in experimental cancer cachexia","volume":"93","author":"Khal","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2019.04.003_bib27","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc927","article-title":"Cachexia in cancer patients","volume":"2","author":"Tisdale","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clcc.2019.04.003_bib28","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/sj.bjc.6603446","article-title":"Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer","volume":"95","author":"Deans","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2019.04.003_bib29","doi-asserted-by":"crossref","first-page":"26055","DOI":"10.1016\/S0021-9258(19)74276-8","article-title":"Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates","volume":"268","author":"Feinstein","year":"1993","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clcc.2019.04.003_bib30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MOG.0b013e3283347e77","article-title":"Cancer cachexia","volume":"26","author":"Tisdale","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.clcc.2019.04.003_bib31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejso.2014.10.056","article-title":"The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review","volume":"41","author":"Malietzis","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2019.04.003_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01635581.2014.894103","article-title":"Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer","volume":"66","author":"Barret","year":"2014","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.clcc.2019.04.003_bib33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2214\/AJR.17.18020","article-title":"Progressive sarcopenia in patients with colorectal cancer predicts survival","volume":"210","author":"Deng","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.clcc.2019.04.003_bib34","doi-asserted-by":"crossref","first-page":"e0129742","DOI":"10.1371\/journal.pone.0129742","article-title":"Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer","volume":"10","author":"Miyamoto","year":"2015","journal-title":"PLoS One"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818305553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818305553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:31Z","timestamp":1761519991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002818305553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1533002818305553"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2019.04.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}